CR Sanjiu Reports Revenue Growth Amid Profit Decline in 2025 Q3
China Resources Pharmaceutical Group Ltd. (HK:3320) reported a revenue increase to RMB 21.99 billion for the nine months ending September 30, 2025, up from RMB 19.74 billion, despite a net profit decline to RMB 2.90 billion from RMB 3.24 billion. The financial results indicate a decrease in cash and cash equivalents, alongside a rise in total assets and liabilities. Analysts rate the stock as a Hold with a price target of HK$5.50. The company operates in the pharmaceutical sector and has a market cap of HK$30.6 billion.
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has provided an update.
CR Sanjiu reported its unaudited financial results for the nine months ending September 30, 2025, showing a revenue increase to RMB 21.99 billion from RMB 19.74 billion in the previous year, despite a decline in net profit to RMB 2.90 billion from RMB 3.24 billion. The financials highlight a net decrease in cash and cash equivalents and a significant rise in total assets and liabilities, indicating potential adjustments during auditing, and advising caution for shareholders and investors.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Sanjiu Medical & Pharmaceutical Company Limited (CR Sanjiu) is a subsidiary of China Resources Pharmaceutical Group Limited, operating in the pharmaceutical industry. The company is listed on the Shenzhen Stock Exchange and primarily focuses on medical and pharmaceutical products.
Average Trading Volume: 16,744,630
Technical Sentiment Signal: Sell
Current Market Cap: HK$30.6B
